Independent Investors Inc. trimmed its position in Amgen, Inc. (NASDAQ:AMGN) by 2.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,936 shares of the medical research company’s stock after selling 900 shares during the quarter. Amgen comprises 2.7% of Independent Investors Inc.’s investment portfolio, making the stock its 7th biggest position. Independent Investors Inc.’s holdings in Amgen were worth $6,216,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Arlington Partners LLC increased its position in shares of Amgen by 86.7% in the 4th quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 65 shares during the last quarter. Moody National Bank Trust Division purchased a new stake in shares of Amgen in the 4th quarter valued at approximately $81,000. Mainstay Capital Management LLC ADV purchased a new stake in shares of Amgen in the 2nd quarter valued at approximately $111,000. Polaris Greystone Financial Group LLC purchased a new stake in shares of Amgen in the 3rd quarter valued at approximately $166,000. Finally, Wellington Shields Capital Management LLC purchased a new stake in shares of Amgen in the 3rd quarter valued at approximately $202,000. Institutional investors own 76.88% of the company’s stock.
Shares of AMGN opened at $200.56 on Monday. The company has a quick ratio of 2.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.05. The stock has a market capitalization of $127.68 billion, a PE ratio of 15.94, a P/E/G ratio of 2.05 and a beta of 1.32. Amgen, Inc. has a 52-week low of $163.31 and a 52-week high of $210.19.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.45 by $0.24. The business had revenue of $5.90 billion during the quarter, compared to the consensus estimate of $5.78 billion. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The business’s revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the firm posted $3.27 EPS. On average, equities research analysts forecast that Amgen, Inc. will post 14.24 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be issued a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.89%. The ex-dividend date is Thursday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $1.32. Amgen’s dividend payout ratio (DPR) is currently 41.97%.
In other news, SVP Cynthia M. Patton sold 1,777 shares of the stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $202.88, for a total value of $360,517.76. Following the completion of the transaction, the senior vice president now owns 23,090 shares in the company, valued at approximately $4,684,499.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Tyler Jacks sold 20,000 shares of the stock in a transaction dated Thursday, December 6th. The shares were sold at an average price of $195.41, for a total transaction of $3,908,200.00. Following the completion of the transaction, the director now owns 28,979 shares of the company’s stock, valued at approximately $5,662,786.39. The disclosure for this sale can be found here. Company insiders own 0.27% of the company’s stock.
A number of equities research analysts have commented on the stock. reissued a “buy” rating and issued a $224.00 price objective on shares of Amgen in a research report on Monday, October 1st. Jefferies Financial Group restated a “buy” rating and issued a $220.00 target price on shares of Amgen in a report on Monday, October 1st. Oppenheimer restated a “buy” rating and issued a $224.00 target price on shares of Amgen in a report on Tuesday, October 2nd. Royal Bank of Canada set a $193.00 target price on shares of Amgen and gave the company a “neutral” rating in a report on Friday, September 28th. Finally, Cantor Fitzgerald initiated coverage on shares of Amgen in a report on Monday, October 1st. They issued a “neutral” rating and a $223.00 target price for the company. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $205.90.
TRADEMARK VIOLATION WARNING: This report was reported by Stock Observer and is the property of of Stock Observer. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.thestockobserver.com/2019/01/14/independent-investors-inc-has-6-22-million-holdings-in-amgen-inc-amgn.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Recommended Story: How much can an individual set aside as a catch-up contribution?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.